Type 2 diabetes and clinical trials

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

Analysis of the renal outcomes of patients in the LEADER trial confirms that the glucagon-like peptide-1 analog liraglutide has a renoprotective effect in patients with type 2 diabetes and increased cardiovascular risk.

A machine-learning analysis suggests the existence of heterogeneous treatment effects in the Look AHEAD trial, which could account for the overall neutral effect of the study intervention on cardiovascular outcomes.

Liraglutide enhances the positive effects of lifestyle intervention on weight loss and glycemic control in patients with prediabetes, show the 3-year outcomes of the SCALE Obesity and Prediabetes trial.

A post-hoc analysis of the Look AHEAD trial suggests that weight loss can avert cardiovascular disease events in overweight patients with Type 2 diabetes.